Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microcrystalline cellulose is a purified, partially depolymerized cellulose that serves as a widely used pharmaceutical excipient. In the clinical trial landscape, specifically in a Phase 3 study sponsored by Vedic Lifesciences Pvt. Ltd. (NCT04722185), it is utilized as a pharmacologically inactive placebo comparator. The study aims to evaluate the efficacy and tolerability of *Andrographis paniculata* and *Aristotelia chilensis* extracts in adults suffering from upper respiratory tract infections (URTI), including symptoms associated with the common cold and COVID-19. As a placebo, it is designed to be indistinguishable from the active treatment to ensure the integrity of the double-blind study design.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microcrystalline cellulose.